Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy, Radiation.

Martin-Luther-Universitat, Halle, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:3City/State/Province:Halle
Treatments:Chemotherapy, RadiationHospital:Martin-Luther-Universitat
Drugs:Journal:Link
Date:Oct 2002

Description:

Patients: This Phase I study involved 36 patients. 92% of patients had newly diagnosed rectal cancer.

Treatment: Treatment consisted of concurrent radiotherapy and the chemotherapy drug Capecitabine (xeloda).

Toxicity: Patients in this maximum tolerated dose study experienced grade 3 hand-foot syndrome, skin rash and perinatal toxicity. Other toxicities (less than grade 3) included: hematologic, infection, gastrointestinal, hepatic, genitourinary, alopecia, cardiovascular, neurologic, flu-like symptoms, metabolic, endocrine, and ocular.

Results: A clinical partial response was reported in nine of ten patients. Overall survival was not discussed.

Support: This study was supported in part by a grant from Hoffman-La Roche.

Correspondence: Jurgen Dunst, MD




Back